このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Vascular Biogenics マネジメント

マネジメント基準チェック /44

Vascular Biogenics'の CEO はDror Haratsで、 Jan2001年に任命され、の在任期間は 22.75年です。の年間総報酬は$ 887.62Kで、 40.3%給与と59.7%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の1.47%を直接所有しており、その価値は$ 177.68K 。経営陣と取締役会の平均在任期間はそれぞれ17.8年と5.4年です。

主要情報

Dror Harats

最高経営責任者

US$887.6k

報酬総額

CEO給与比率	40.3%
CEO在任期間	22.8yrs
CEOの所有権	1.5%
経営陣の平均在職期間	17.8yrs
取締役会の平均在任期間	5.4yrs

経営陣の近況

How Much Are Vascular Biogenics Ltd. (NASDAQ:VBLT) Insiders Spending On Buying Shares?

Mar 17

Recent updates

VBL Therapeutics receives non-compliance letter from Nasdaq

Sep 01

VBL Therapeutics GAAP EPS of -$0.12

Aug 15

VBL Therapeutics' late-stage trial for ovarian cancer treatment does not meet main goals

Jul 19

Here's Why We're Watching Vascular Biogenics' (NASDAQ:VBLT) Cash Burn Situation

May 18

Vascular Biogenics Trial Nears Full Enrollment, Price Could Jump

Sep 03

How Much Are Vascular Biogenics Ltd. (NASDAQ:VBLT) Insiders Spending On Buying Shares?

Mar 17

How Much Of Vascular Biogenics Ltd. (NASDAQ:VBLT) Do Insiders Own?

Jan 28

VBL Therapeutics expands the ovarian cancer trial in Europe

Dec 29

Is Vascular Biogenics (NASDAQ:VBLT) In A Good Position To Deliver On Growth Plans?

Dec 24

Vascular Biogenics Ltd. (NASDAQ:VBLT) Just Reported And Analysts Have Been Cutting Their Estimates

Nov 19

VBL Therapeutics EPS beats by $0.01, misses on revenue

Nov 16

CEO報酬分析

Vascular Biogenics の収益と比較して、Dror Harats の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Jun 30 2023	n/a	n/a	-US$16m
Mar 31 2023	n/a	n/a	-US$25m
Dec 31 2022	US$888k	US$357k	-US$32m
Sep 30 2022	n/a	n/a	-US$38m
Jun 30 2022	n/a	n/a	-US$35m
Mar 31 2022	n/a	n/a	-US$34m
Dec 31 2021	US$1m	US$349k	-US$30m
Sep 30 2021	n/a	n/a	-US$28m
Jun 30 2021	n/a	n/a	-US$27m
Mar 31 2021	n/a	n/a	-US$25m
Dec 31 2020	n/a	n/a	-US$24m
Sep 30 2020	n/a	n/a	-US$23m
Jun 30 2020	n/a	n/a	-US$22m
Mar 31 2020	n/a	n/a	-US$21m
Dec 31 2019	US$889k	US$405k	-US$19m
Sep 30 2019	n/a	n/a	-US$18m
Jun 30 2019	n/a	n/a	-US$18m
Mar 31 2019	n/a	n/a	-US$17m
Dec 31 2018	US$815k	US$375k	-US$20m
Sep 30 2018	n/a	n/a	-US$10m
Jun 30 2018	n/a	n/a	-US$11m
Mar 31 2018	n/a	n/a	-US$12m
Dec 31 2017	n/a	n/a	-US$10m
Sep 30 2017	n/a	n/a	-US$21m
Jun 30 2017	n/a	n/a	-US$18m
Mar 31 2017	n/a	n/a	-US$16m
Dec 31 2016	US$515k	US$406k	-US$16m

報酬と市場: Drorの総報酬 ($USD 887.62K ) は、 US市場 ($USD 667.63K ) の同様の規模の企業の平均とほぼ同じです。

報酬と収益: Drorの報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

Dror Harats (66 yo)

22.8yrs

在職期間

US$887,624

報酬

Prof. Dror Harats, MD, has been the Chief Executive Officer of Vascular Biogenics Ltd., since January 2001. Prof. Harats founded VBL in 2000 based on many years of research in Atherosclerosis, Vascular Bio...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Dror Harats	CEO & Director	22.8yrs	US$887.62k	1.47% $ 177.7k
Samuel Backenroth	Chief Financial Officer	2yrs	US$669.08k	0.68% $ 81.9k
Eyal Breitbart	Senior Vice President of Research & Operations	17.8yrs	US$433.79k	データなし
Ayelet Horn	General Counsel	23.8yrs	データなし	データなし
Erez Feige	Senior Vice President of Business Operations	1.7yrs	US$374.71k	データなし

17.8yrs

平均在職期間

52yo

平均年齢

経験豊富な経営陣: VBLTの経営陣は経験豊富で経験豊富です（平均在職期間は17.8年）。

取締役

名称	ポジション	在職期間	報酬	所有権
Dror Harats	CEO & Director	22.8yrs	US$887.62k	1.47% $ 177.7k
Ruth Alon	Independent Non-Executive Director	13.6yrs	US$94.25k	0% $ 0
David Hastings	Independent Non-Executive Director	5.8yrs	US$101.30k	0% $ 0
Ruth Arnon	Scientific Consultant & Member of Scientific Advisory Board	2.3yrs	データなし	データなし
Marc Kozin	Independent Non-Executive Chairman	3yrs	US$205.67k	0.050% $ 6.1k
Shmuel Ben-Zvi	Independent Non-Executive Director	5.1yrs	US$96.88k	0.077% $ 9.4k
Patrick Wen	Member of Scientific Advisory Board	no data	データなし	データなし
Andrew Brenner	Member of Scientific Advisory Board	no data	データなし	データなし
Richard Penson	Member of Scientific Advisory Board	no data	データなし	データなし
Timothy Cloughesy	Member of Scientific Advisory Board	no data	データなし	データなし
Nicholas Butowski	Member of Scientific Advisory Board	no data	データなし	データなし
Kathleen Moore	Member of Scientific Advisory Board	no data	データなし	データなし

5.4yrs

平均在職期間

64.5yo

平均年齢

経験豊富なボード: VBLTの取締役会は経験豊富であると考えられます ( 5.4年の平均在任期間)。

Vascular Biogenics マネジメント

マネジメント 基準チェック /44

主要情報

経営陣の近況

Vascular Biogenics Ltd. Approves Board Appointments

Vascular Biogenics Ltd., Annual General Meeting, Jul 07, 2022

High number of new directors

How Much Are Vascular Biogenics Ltd. (NASDAQ:VBLT) Insiders Spending On Buying Shares?

Vascular Biogenics Ltd. Announces Resignation of Susan Kelley as an Independent Director

Vascular Biogenics Ltd. Announces Board Changes

Recent updates

Vascular Biogenics Ltd.(NasdaqCM:VBLT) dropped from NASDAQ Composite Index

Notable Labs, Inc. completed the acquisition of Vascular Biogenics Ltd. (NasdaqGM:VBLT) from Aurum Ventures MKI Ltd. and others in reverse merger transaction.

Vascular Biogenics Ltd. Approves Board Appointments

Vascular Biogenics Ltd. Receives Non-Compliance Notice from Nasdaq

Full year 2022 earnings released: US$0.42 loss per share (vs US$0.45 loss in FY 2021)

An unknown buyer entered into an agreement to acquire Manufacturing facility in Modiin, Israel and certain related assets from Vascular Biogenics Ltd. (NasdaqGM:VBLT) for $7.1 million.

VBL Therapeutics Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

VBL Therapeutics receives non-compliance letter from Nasdaq

VBL Therapeutics GAAP EPS of -$0.12

VBL Therapeutics Announces Workforce Reduction

Price target increased to US$6.00

Vbl Therapeutics Announces Top-Line Data from Phase 3 Oval Trial of Ofra-Vec in Patients with Platinum-Resistant Ovarian Cancer

VBL Therapeutics' late-stage trial for ovarian cancer treatment does not meet main goals

Vascular Biogenics Ltd., Annual General Meeting, Jul 07, 2022

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Consensus forecasts updated

Here's Why We're Watching Vascular Biogenics' (NASDAQ:VBLT) Cash Burn Situation

Vascular Biogenics Ltd. to Report Q1, 2022 Results on May 17, 2022

Consensus forecasts updated

No longer forecast to breakeven

VBL Therapeutics Announces U.S. Food and Drug Administration Grants Fast Track Designation for Ofra-Vec (Ofranergene Obadenovec or VB-111) in Combination with Paclitaxel for Treatment of Platinum-Resistant Ovarian Cancer

Consensus forecasts updated

VBL Therapeutics Announces Completion of Enrollment in OVAL Phase 3 Registration-Enabling Trial of Ofra-Vec in Ovarian Cancer and Unanimous Recommendation by Independent Data Safety Monitoring Committee to Continue Study as Planned

Forecast to breakeven in 2024

Vascular Biogenics Ltd. announced that it expects to receive €15 million in funding from European Innovation Council

Third quarter 2021 earnings released: US$0.092 loss per share (vs US$0.12 loss in 3Q 2020)

VBL Therapeutics Announces Independent Data Safety Monitoring Committee Provides Clearance to Continue the Oval Phase 3 Registration-Enabling Study of VB-111 in Ovarian Cancer

Vascular Biogenics Trial Nears Full Enrollment, Price Could Jump

Second quarter 2021 earnings released: US$0.12 loss per share (vs US$0.14 loss in 2Q 2020)

High number of new directors

VBL Therapeutics Provides Update on Oval, A Phase 3 Registration Enabling Study of VB-111 in Ovarian Cancer

VBL Therapeutics Announces Addition of Progression Free Survival as A Second Primary Endpoint in OVAL, A Phase 3 Registration Enabling Study of VB-111 in Ovarian Cancer

Vbl Therapeutics to Provide an Update on the Oval Phase 3 Registration Enabling Study of Vb-111 in Ovarian Cancer At the 2021

Price target increased to US$5.20

Consensus forecasts updated

First quarter 2021 earnings released: US$0.12 loss per share (vs US$0.15 loss in 1Q 2020)

Consensus forecasts updated

Full year 2020 earnings released: US$0.56 loss per share (vs US$0.54 loss in FY 2019)

Vascular Biogenics Ltd. to Report Q4, 2020 Results on Mar 25, 2021

How Much Are Vascular Biogenics Ltd. (NASDAQ:VBLT) Insiders Spending On Buying Shares?

VBL Therapeutics Announces Patient Dosing Initiated in Randomized, Controlled and Blinded Trial of VB-111 in Patients with Recurrent Glioblastoma Multiforme

VBL Therapeutics Announces Data Safety Monitoring Committee Provides Green Light to Advance the OVAL Phase 3 Registration Enabling Study of VB-111 in Ovarian Cancer

VBL Therapeutics Treats First Patient in Phase 2 Randomized Controlled Study of VB-201 in COVID-19 Patients

How Much Of Vascular Biogenics Ltd. (NASDAQ:VBLT) Do Insiders Own?

New 90-day high: US$2.50

Price target raised to US$4.50

VBL Therapeutics Announces First Patient in Europe in the OVAL Trial

VBL Therapeutics expands the ovarian cancer trial in Europe

Is Vascular Biogenics (NASDAQ:VBLT) In A Good Position To Deliver On Growth Plans?

New 90-day high: US$1.96

Vascular Biogenics Ltd. (NASDAQ:VBLT) Just Reported And Analysts Have Been Cutting Their Estimates

Third quarter 2020 earnings released: US$0.12 loss per share

Revenue and earnings miss expectations

VBL Therapeutics EPS beats by $0.01, misses on revenue

New 90-day low: US$1.07

Vascular Biogenics Ltd. to Report Q3, 2020 Results on Nov 16, 2020

Vascular Biogenics Ltd. Announces Resignation of Susan Kelley as an Independent Director

Vascular Biogenics Ltd. Announces Board Changes

New 90-day low - US$1.16

First half earnings released

Vascular Biogenics Ltd. to Report Q2, 2020 Results on Aug 13, 2020

CEO報酬分析

CEO（最高経営責任者

在職期間

報酬

リーダーシップ・チーム

平均在職期間

平均年齢

取締役

マネジメント基準チェック /44